Radioactive Antibody "Missiles" Home In on HIV















Share on Tumblr

HIV

ANTIBODIES LINKED to radioactive isotopes home in on and kill HIV-infected human cells in mice. Image: ¿ MICHAEL FREEMAN/CORBIS

  • What a Plant Knows

    How does a Venus flytrap know when to snap shut? Can it actually feel an insect’s tiny, spindly legs? And how do cherry blossoms know when to bloom? Can they...

    Read More »

It worked for treating cancer; now researchers have found they can send dollops of lethal radiation directly into HIV-infected cells using radioactive antibodies. So far the technique only works in mice, but investigators hope they can extend their proof-of-concept to a treatment capable of destroying all of the infected cells in a person's body under some circumstances. "Twenty-five years from the start of the epidemic, HIV is still an incurable disease--something completely different needs to be done to completely eradicate it," says nuclear medicine specialist Ekaterina Dadachova of the Albert Einstein College of Medicine in New York City, first author of a report published November 6 in PLoS Medicine that describes the results.

Antiretroviral drugs keep HIV at bay but do not kill the virus. Instead they stop it from reproducing and let the immune system clear out infected cells. Dadachova and her colleagues reasoned they could kill these cells directly and with minimal harm to the rest of the body if they could make radioactive isotopes cluster around the cells. Researchers have already found success against certain cancers by attaching radioactive isotopes to antibodies that seek out tumor cells. So the team linked radioactive bismuth 213 and rhenium 188 to antibodies designed to stick to two HIV proteins (gp41 and gp120) displayed on the surface of infected cells. To see if the antibodies would home in on the offending cells, they injected the compound into mice that contained human blood cells infected with HIV. The compound appeared to work safely: the treated mice had less than half the quantity of infected cells that their untreated counterparts did, and the animals suffered collateral damage to healthy blood cells only at the highest antibody dose, the group reports. Dadachova says the team is working with a pharmaceutical company to see if a clinical trial is warranted.

In principle, the technique could supplement antiretroviral therapy for a brief time, especially very early in an infection before the immune response has kicked in, says AIDS vaccine researcher David Montefiori of Duke University. "This is the type of treatment technology that gives one hope it might be possible to eliminate the virus," he says. Major uncertainties remain, though. As HIV infections progress, some infected cells go dormant and do not cover themselves in the proteins, or antigens, that antibodies recognize. Treatment, let alone cure, is only possible, Montefiori says, "if this therapy is effective in killing HIV -infected cells in humans, as it was in mice, and if the latently infected cells can be induced to express viral antigens. Those are two big if's."



Comments

Add Comment
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Radioactive Antibody "Missiles" Home In on HIV

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X